It was shown that the dynamics in the amorphous phase controlled the drift mobility of free charge carriers and, by that, determined the tau of the space charge relaxation process. The structuring processes during the recrystallization also affected the parameters of the order-disorder transition in the low-perfect ferroelectric (antiferroelectric) phase. (C) 2010 Wiley Periodicals, Inc. J Appl Polym Sci 120: 13-20, 2011″
“Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes. Cancer is a disease S63845 of older people and, as the population ages over the next 10-20 years, we can expect an increase in

the cancer incidence. Encouragingly, cancer mortality has stabilized in many countries. Part of this success may be attributed to the development of new cancer agents, collectively called ‘targeted therapies’, that are more specific to key components of tumour growth. Worldwide, however, one of the main factors that limit patient access to these important new drugs is their cost, which is higher than traditional chemotherapy.

In this review, the clinical and pharmacoeconomic data of selected targeted agents are discussed. In the second part of this article, the challenges faced by healthcare systems in making such drugs available to patients Selleck CP 456773 is reviewed. Current strategies used by many countries around the world to manage cancer drug budgets are presented, along with a proposed approach using pharmacoeconomic methodology that may increase patient access.”
“The Food and Drug Administration (FDA) approved the New Drug Application for Wellbutrin

sustained release (SR) 100 mg tablets on October 4, 1996. However, by 1998, the FDA expressed concern about the stability of this drug product based on an increase in the dissolution pro. le on storage. Data submitted in the annual report showed that this drug product could not meet the expiry of 18 months Selleckchem EPZ5676 at the International Committee on Harmonization storage condition of 25 degrees C/60% relative humidity. The FDA mandated a 12-month expiry and GlaxoWellcome tightened this further by instituting an expiry of 9 months. The FDA also requested a long-term solution to the stability of Wellbutrin SR 100 mg tablets. Investigations via colloidal solutions revealed that the dissolution rate increase on storage occurred due to acid hydrolysis of the release controlling polymer. This drug product was successfully reformulated by slowing the initial dissolution rate and having an increased ratio of release controlling polymer to acid stabilizer. The reformulation used the same ingredients and manufacturing unit processes as the original formulation. The reformulated drug product was approved by the FDA on October 11, 2000 with an 18-month shelf-life.